Cargando…

Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis

BACKGROUND: We aimed to clarify the benefits of the addition of rh‐endostatin into concurrent chemoradiotherapy (CCRT) versus CCRT alone for locally advanced non‐small cell lung cancer (NSCLC) by a meta‐analysis. METHODS: PubMed, Embase, Cochrane Central Register of Controlled Trials, Wanfang and Ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Meng, Zhai, Yirui, Men, Yu, Wang, Jianyang, Deng, Lei, Wang, Wenqing, Bao, Yongxing, Yang, Xu, Sun, Shuang, Ma, Zeliang, Liu, Yunsong, Wang, Jun, Zhu, Hui, Hui, Zhouguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636201/ https://www.ncbi.nlm.nih.gov/pubmed/34676669 http://dx.doi.org/10.1111/1759-7714.14188

Ejemplares similares

Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis
por: Liu, Yunsong, et al.
Publicado: (2023)

Higher Lung and Heart Doses Decrease Early and Long-Term Survival, Respectively, in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation
por: Ma, Zeliang, et al.
Publicado: (2023)

Enhanced prediction of postoperative radiotherapy‐induced esophagitis in non‐small cell lung cancer: Dosiomic model development in a real‐world cohort and validation in the PORT‐C randomized controlled trial
por: Ma, Zeliang, et al.
Publicado: (2023)

Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer
por: Yuan, Meng, et al.
Publicado: (2022)

Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer
por: Yuan, Meng, et al.
Publicado: (2022)

Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study
por: Yin, Yuanxiu, et al.
Publicado: (2022)

Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma
por: Li, Yuan, et al.
Publicado: (2019)

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy
por: Zhou, Shengyu, et al.
Publicado: (2018)

Risk of cardiac‐related mortality in stage IIIA‐N2 non‐small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database
por: Sun, Xin, et al.
Publicado: (2021)

Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non‐small cell lung cancer: Updated follow‐up results from two phase II trials
por: Honglian, Ma, et al.
Publicado: (2020)

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
por: Chen, Chen, et al.
Publicado: (2019)

Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice
por: Ma, Xingqun, et al.
Publicado: (2012)

The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients
por: Yuan, Meng, et al.
Publicado: (2021)

Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis
por: Ma, Zeliang, et al.
Publicado: (2021)

Comparison of different neoadjuvant treatments for resectable locoregional esophageal cancer: A systematic review and network meta‐analysis
por: Bao, Yongxing, et al.
Publicado: (2022)

Additional Radiotherapy With or Without Chemotherapy Following Endoscopic Resection for Stage I Esophageal Carcinoma: A Pilot Study
por: Yang, Xu, et al.
Publicado: (2021)

The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
por: Zhang, Tao, et al.
Publicado: (2020)

Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma
por: Zhai, Yirui, et al.
Publicado: (2022)

Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer
por: Biaoxue, Rong, et al.
Publicado: (2012)

Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer
por: Lu, Heming, et al.
Publicado: (2022)

Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
por: Xing, Peipei, et al.
Publicado: (2016)

Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients
por: Kang, Jingjing, et al.
Publicado: (2018)

High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis
por: Sun, Xin, et al.
Publicado: (2020)

Recombinant Human Endostatin Endostar Inhibits Tumor Growth and Metastasis in a Mouse Xenograft Model of Colon Cancer
por: Jia, Yitao, et al.
Publicado: (2011)

Endostar, a Modified Recombinant Human Endostatin, Suppresses Angiogenesis through Inhibition of Wnt/β-Catenin Signaling Pathway
por: Xu, Xiaoming, et al.
Publicado: (2014)

Combined neat model for the prognosis of postoperative stage III‐N2 non‐small cell lung cancer
por: Zhai, Yirui, et al.
Publicado: (2020)

Postoperative radiotherapy for pathological stage IIIA‐N2 non‐small cell lung cancer with positive surgical margins
por: Yuan, Meng, et al.
Publicado: (2020)

Endostar (rh‐endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non‐small cell lung cancer: A meta‐analysis
por: An, Jihong, et al.
Publicado: (2018)

Efficacy of bronchoscopic intratumoral injection of endostar and cisplatin in lung squamous cell carcinoma patients underwent conventional chemoradiotherapy
por: Ji, Yanzhen, et al.
Publicado: (2023)

Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy
por: Yang, Yufan, et al.
Publicado: (2021)

Postoperative radiotherapy improves survival of patients with ypN2 non‐small cell lung cancer after neoadjuvant chemotherapy followed by surgery – A propensity score matching study of the Surveillance, Epidemiology, and End Results database
por: Bao, Yongxing, et al.
Publicado: (2021)

The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma
por: Guan, Ying, et al.
Publicado: (2015)

Clinical effects of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection on malignant central airway obstruction: a retrospective analysis of 319 cases
por: Zhou, Yunzhi, et al.
Publicado: (2021)

A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis
por: Sun, Shuang, et al.
Publicado: (2021)

Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas
por: Liao, Zhichao, et al.
Publicado: (2022)

The Efficacy and Safety of Continuous Intravenous Endostar Treatment Combined With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Squamous Cell Carcinoma: A Randomized Controlled Trial
por: Shu, Hang, et al.
Publicado: (2021)

Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy
por: Gao, Lin-Rui, et al.
Publicado: (2022)

Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer
por: Xu, Kunpeng, et al.
Publicado: (2021)

Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in China
por: Zhou, Shujie, et al.
Publicado: (2023)

Intensity-modulated radiation therapy (IMRT)-based concurrent chemoradiotherapy (CCRT) with Endostar in patients with pelvic locoregional recurrence of cervical cancer: Results from a hospital in the Qinghai-Tibet Plateau
por: Zhang, Kuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_thiq2l0n24fv946juqikergfks